PubMed Health⌕ Search

PubMed · 10366494

Size limitations in semicircular duct systems

Abstract

The present article discusses mechanical requirements and limitations which are applicable to the construction of the system of semicircular ducts, especially to its size. The simplified case of a single, uniform duct system has been considered which can be described by a second order equation of motion. The principal functional quantities for this rotation-sensor are: (1) response speed; (2) sensitivity; and (3) regular flow. The response speed of a single, uniform semicircular duct is characterized by the short time constant (T2) which is dependent on the duct radius (r). Its estimated range is from 0.04 ms in the smallest to 140 ms in the largest known labyrinth. The sensitivity is characterized by the maximal endolymph displacement after a step stimulus (xmax). Its estimated range is from 0.0016 &mgr;m to 5.97 mm (6.56 decades!), assuming an input angular velocity of omega=1 rad s-1. The Reynolds number is a measure for an undisturbed laminar flow. Its estimated range varies from 7.38.10(-4)to 45.1 for omega=1 rad s-1. The above data follow from graphs in which, for a single uniform duct, circuit radius (R) is plotted against duct radius (r) for labyrinths of 233 species belonging to different vertebrate-groups. A relation R =38.9. r1.60was determined. The smallest labyrinth was found in a carp larva (Cyprinus), the largest in a whale shark (Rhincodon). Large whales possess labyrinths of average mammalian size. It is revealed that semicircular duct size is bound by requirements concerning regular flow and by a too low response speed for large labyrinths, and by a too low sensitivity for small labyrinths. Other important quantities are mechanical amplification factors which are a consequence of more complex vestibular constructions than a single uniform duct circuit. Allometric relationships are interpreted as compromises between the quantities mentioned. A hypothesis for the relatively large semicircular duct sizes of fishes, especially Elasmobranchii, compared with mammals and birds is presented. Copyright 1999 Academic Press.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Muller. 1999-06-07. Size limitations in semicircular duct systems. https://doi.org/10.1006/jtbi.1999.0922

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗